본문 바로가기

MXene/Au nanorods synergized electrochemical interface for sensitive DDC detection in serum from Parkinson's disease patients

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
MICROCHEMICAL JOURNAL230 · #119846 · 2026
피인용
Web of Science 0Scopus 0
JCR IF
JCR 2024 5.1
ISSN
0026-265X

저자

  1. Xu, Xiaohui제1저자Wannan Med Univ, Anhui Prov Key Lab Basic Res & Transformat Age rel, Wuhu 241002, Peoples R China
  2. Wang, XinyueShanghai Univ, Qianweichang Coll, Shanghai 200444, Peoples R China
  3. Xie, QiangShanghai Univ, Qianweichang Coll, Shanghai 200444, Peoples R China
  4. Wu, JingyaoShanghai Univ, Qianweichang Coll, Shanghai 200444, Peoples R China
  5. 고광락교신저자Pusan Natl Univ, Inst Gen Educ, Busan 609735, South Korea
  6. Chen, Hongxia교신저자Shanghai Univ, Qianweichang Coll, Shanghai 200444, Peoples R China

초록

Parkinson's disease (PD) management requires point-of-care accessible tools for personalized monitoring of levodopa therapy. Plasma dopa decarboxylase (DDC), a drug-responsive biomarker, has emerged as a promising target to guide dosing and anticipate adverse effects. However, current DDC assays rely on costly, labor intensive platforms that preclude rapid, sensitive detection in complex biological fluids. Here we report an electrochemical biosensor based on a novel ternary supramolecular interface combining MXene, Au nanorods, and p-sulfonatocalix[4]arene (pSC(4)). In this design, pSC(4) serves as a supramolecular adapter to orient anti DDC antibodies via host-guest recognition, while the MXene/AuNRs hybrid provides synergistic signal amplification and contributes to reduced nonspecific adsorption. The sensor achieves a detection limit of 1.15 ng mL(-1) and a linear range of 10-200 ng mL(-1) in undiluted human serum, representing an approximately 5.7 fold signal amplification over single component devices. In an exploratory study of 12 subjects (6 PD patients under chronic dopaminergic therapy, 6 healthy controls), sera from PD patients showed a significantly higher Delta Rct than controls (approximately threefold, P < 0.001). This work establishes an analytical proof-of-concept for DDC detection by integrating supramolecular chemistry with nanomaterials, providing a foundation for future clinical studies.

키워드

MXeneDopa decarboxylaseParkinson's diseaseAu nanorodsMONOLAYER

식별자

Scopus EID
2-s2.0-105051975225
WoS UID
001892756100001